OasisLMS

NMIBC Global Exchange: AUA-JUA Edition

Live Virtual Course: Friday, November 6, 2026 | 6:30-7:30 am EST/8:30-9:30 pm JST

NMIBC Global Exchange: AUA-JUA Edition will be presented by the American Urological Association (AUA) in partnership with the Japanese Urological Association (JUA) and will include a U.S. based moderator and panel of American and Japanese faculty. The 60-minute live virtual course will be offered in English with simultaneous AI-based translation in 60+ languages. 

This course will explore contemporary approaches to the diagnosis, staging, and risk stratification of NMIBC, with a focus on the management of high-risk disease, including initial treatment with BCG and then subsequent therapeutic options for patients with disease recurrence after BCG. Experts from Japan and the United States will discuss management options following BCG failure, including bladder-preserving strategies and the role of radical cystectomy. Through an international exchange of perspectives, this webinar will highlight key considerations in the clinical decision-making and provide practical insights tailored to the needs of Japanese clinicians. 

Presented in English and using the AI based translation technology Wordly, this activity is of value to the global urologic community.

This live virtual event will offer simultaneous translation in 60+ languages. Powered by an involved AI based technology Wordly, attendees will be able to access the audio and captioning translations in real time to help make the course more accessible to our colleagues around the globe.

Acknowledgements:

Independent educational grant support provided by:

• Ferring Pharmaceuticals 

• Urologists

After participating in this CME activity, participants will be able to:

1. Apply contemporary approaches to diagnosis, staging, and risk stratification.
2. Discuss evidence-based treatment strategies across the high-risk NMIBC continuum.
3. Recognize challenges associated with BCG therapy and BCG failure.
4. Evaluate bladder-preserving and surgical treatment options, incorporating efficacy, toxicity, and patient preferences into clinical decision-making.
5. Compare similarities and differences in NMIBC management between Japan and the United States.

Education Council Disclosures

Education Council Disclosures (2026)

COI Work Group Disclosures

COI Work Group Disclosures (2026)

Faculty Disclosures 

Faculty disclosures will be posted here prior to the start of the course.

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

NMIBC Global Exchange: AUA-JUA Edition (2026)
Friday, Novemeber 6, 2026 | 6:30-8:30 am EST/8:30-9:30 pm JST

Welcome 

Pre-test 

• Segment 1: Diagnosis, Staging, and Risk Stratification
• Segment 2: Initial Management of High-Risk NMIBC and BCG Treatment
• Segment 3: Treatment Options Following BCG Failure: Bladder Preservation Versus Cyctectomy

Q&A Session

ACCREDITATION: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: The American Urological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit^TM.

EVIDENCE BASED CONTENT: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: All persons in a position to control the content of a CME activity are required to disclose to the AUA, as the ACCME-accredited provider, all financial relationships with any ineligible company (formerly commercial interests) during the previous 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The AUA must determine if the individual’s relationships are relevant to the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners with information so they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of relevant financial relationships that result in conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation.

AUA COMMITTMENT: AUA is committed to providing a safe and productive meeting environment that fosters open dialogue and the exchange of scientific ideas and is free of harassment and discrimination. All meeting participants are expected to behave professionally and treat others with respect, follow venue rules, and alert AUA staff or security of any dangerous situations or anyone in distress. 

REPORTING HARRASSMENT: It is the policy of the AUA that all meeting participants will enjoy an environment free from discrimination, harassment or retaliation. Harassing behavior by meeting participants will not be tolerated. If an individual experiences or witnesses harassment, he or she should contact Janet Skorepa, AUA EVP, at jskorepa@AUAnet.org or Maureen E. Cones, Esq., AUA General Counsel, at mcones@auanet.org or use a venue phone and ask for security if he or she feels unsafe. All complaints will be treated seriously and responded to promptly. 

The AUA reserves the right to take any action deemed necessary and appropriate, including refusing or revoking the registration of any individual, without refund, as long as such refusal is consistent with applicable law and AUA policy. 

DISCLAIMER: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association (AUA). 

CONSENT TO USE PHOTOGRAPHIC IMAGES: Registration and attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the registrant or attendee's image or voice in photographs, videotapes, electronic reproductions, and audiotapes of such events and activities. 

AUDIO, VIDEO, PHOTOGRAPHIC EQUIPMENT: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.